Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment

BACKGROUND/AIMS: Adalimumab dose escalation is one of the most important options in refractory Crohn's disease patients with loss of response to adalimumab. The goal of this study was to evaluate the effectiveness of adalimumab dose escalation in Crohn's disease patients with loss of respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Taketo, Mizoshita, Tsutomu, Sugiyama, Tomoya, Hirata, Yoshikazu, Kimura, Yoshihide, Suzuki, Yuka, Yamada, Tomonori, Tsukamoto, Hironobu, Mizushima, Takashi, Sugimura, Naomi, Katano, Takahito, Tanida, Satoshi, Kataoka, Hiromi, Sasaki, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2019
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547276/
https://www.ncbi.nlm.nih.gov/pubmed/31182942
http://dx.doi.org/10.1159/000496453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547276/
https://www.ncbi.nlm.nih.gov/pubmed/31182942
http://dx.doi.org/10.1159/000496453

Ejemplares similares